|
gptkbp:instanceOf
|
gptkb:chemical_compound
benzodiazepine
carbamate
|
|
gptkbp:approvedBy
|
1955
|
|
gptkbp:ATCCode
|
N05BA02
|
|
gptkbp:brand
|
gptkb:Miltown
Equanil
Meprospan
Meprocol
Meprol
Meprolen
Meprosan
Meprotabs
|
|
gptkbp:CASNumber
|
57-53-4
|
|
gptkbp:chemicalFormula
|
C9H18N2O4
|
|
gptkbp:contraindication
|
porphyria
hypersensitivity to meprobamate
|
|
gptkbp:discoveredBy
|
Frank Berger
Bernard John Ludwig
|
|
gptkbp:eliminationHalfLife
|
6–17 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Meprobamate
|
|
gptkbp:IUPACName
|
2-methyl-2-propyl-1,3-propanediol dicarbamate
|
|
gptkbp:KEGGID
|
D08109
|
|
gptkbp:legalStatus
|
Schedule IV controlled substance
|
|
gptkbp:mechanismOfAction
|
GABAA receptor modulator
|
|
gptkbp:meltingPoint
|
120–121 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
218.25 g/mol
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:PubChem_CID
|
CHEMBL651
4067
3927
DB00371
|
|
gptkbp:relatedTo
|
gptkb:carisoprodol
gptkb:mebutamate
|
|
gptkbp:riskFactor
|
overdose
abuse potential
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
drowsiness
dependence
|
|
gptkbp:solubility
|
moderate
|
|
gptkbp:UNII
|
9U1VM840SP
|
|
gptkbp:usedFor
|
treatment of anxiety
|
|
gptkbp:withdrawn_in
|
several countries
|
|
gptkbp:bfsParent
|
gptkb:Depressants
|
|
gptkbp:bfsLayer
|
7
|